Organogenesis Holdings Inc.
ORGO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.91 | -1.58 | -0.27 | 0.04 |
| FCF Yield | 0.99% | 1.22% | -2.58% | 2.59% |
| EV / EBITDA | 20.88 | 15.31 | 9.21 | 13.84 |
| Quality | ||||
| ROIC | 0.09% | 1.49% | 4.37% | 19.25% |
| Gross Margin | 75.99% | 75.42% | 76.71% | 75.57% |
| Cash Conversion Ratio | 16.50 | 6.25 | 1.60 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.25% | -2.50% | 10.05% | 21.44% |
| Free Cash Flow Growth | -36.27% | 172.50% | -129.39% | 351.87% |
| Safety | ||||
| Net Debt / EBITDA | -5.85 | 0.42 | 0.53 | 0.21 |
| Interest Coverage | -0.83 | 5.72 | 11.10 | 9.98 |
| Efficiency | ||||
| Inventory Turnover | 4.41 | 3.77 | 4.24 | 4.56 |
| Cash Conversion Cycle | 74.70 | 60.63 | 46.18 | 50.60 |